Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1313247 | 0.92 | PDGFRB (0.43) | PDGFRBFGFR1KDRALOX15TSHR | |
| SCHEMBL1313859 | 0.81 | PYGL (0.41) | PDGFRBFGFR1KDRTSHRCHRM1 | |
| SCHEMBL12117597 | 0.76 | PDGFRB (0.74) | PDGFRBFGFR1KDRCHRM1CHRM3 | |
| SCHEMBL1312318 | 0.76 | DRD2 (0.49) | TSHRALDH1A1 | |
| SCHEMBL1312796 | 0.73 | ACKR3 (0.41) | PDGFRBFGFR1KDRTSHRCHRM4 | |
| SCHEMBL1312775 | 0.71 | DRD2 (0.41) | PDGFRBFGFR1KDRTSHRALDH1A1 | |
| SCHEMBL1313746 | 0.70 | GAA (0.41) | KDM1AKDRTSHREPHX1 | |
| Hydrochloric Acid SCHEMBL27754601 | 0.70 | ALOX15 (0.54) | KDM1AALOX15TSHRCHRM1CHRM3 | |
| SCHEMBL1312667 | 0.69 | PYGL (0.36) | PDGFRBFGFR1KDRTSHRCHRM1 | |
| SCHEMBL7126911 | 0.67 | PDGFRB (0.42) | PDGFRBFGFR1KDRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2292613-B1 | DIHYDROINDOLINONE DERIVATIVES | SHANGHAI INST PHARM INDUSTRY (CN) | 2015-09-30 | — | — | EP | disclosed |
| US-8829039-B2 | Dihydroindolinone derivatives | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2014-09-09 | — | — | US | disclosed |
| US-20110275671-A1 | DIHYDROINDOLINONE DERIVATIVES | Shanghai Institute of Pharmaceutical Indusrty (CN) | 2011-11-10 | — | — | US | disclosed |
| EP-2292613-A1 | DIHYDROINDOLINONE DERIVATIVES | Shanghai Institute of Pharmaceutical Industry (CN) | 2011-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275671-A1 | DIHYDROINDOLINONE DERIVATIVES | LCK, CDK5, ABL1 | KDM1A 2359/4885PDGFRB 195/4885FGFR1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.